We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




AI-Based CT Imaging Software Offers Paradigm Shift for CVD Screening

By MedImaging International staff writers
Posted on 22 Jul 2022
Print article
Image: ElucidVivo diagnostic imaging software is propelling the fight against CVD (Photo courtesy of Elucid)
Image: ElucidVivo diagnostic imaging software is propelling the fight against CVD (Photo courtesy of Elucid)

Myocardial ischemia occurs when blood flow to the heart is reduced, preventing the heart muscle from receiving enough oxygen. This is often the result of plaque buildup inside the artery wall. Heart attack and stroke are primarily caused by non-obstructive, but unstable plaque in the arteries that goes undiagnosed and untreated. Current non-invasive testing cannot visualize the biology deep inside artery walls where heart disease develops. Now, the only histologically-validated, objective and quantitative CTA-based arterial analysis software helps deliver personalized patient care by utilizing ground-truth histology to inform on heart attack and stroke risk.

ElucidVivo from Elucid (Boston, MA, USA) is a breakthrough FDA-cleared diagnostic imaging software that is propelling the fight against cardiovascular diseases (CVD). Using a combination of powerful image restoration and AI-driven modeling trained on pathology, it enables the identification of risk factors in CVD such as those tissues undetectable by other methods, including lipid-rich necrotic core. Non-invasive CTA, plus ElucidVivo can reduce risks and improve diagnosis for millions suffering from heart disease.

ElucidVivo is the first and only non-invasive image analysis software that employs CT angiography and patented computer algorithms, based on expert histologic examination of thousands of tissue samples, to objectively quantify the extent and stability of arterial plaque for tailored patient care. It helps assess plaque composition with histology-validated software, and quantify heart attack and stroke risk with greater accuracy. ElucidVivo helps visualize a comprehensive and objective view of arterial disease to enable personalized treatment plans before a patient ever enters the hospital.

Related Links:
Elucid 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Illuminator
Trimline Basic
New
X-Ray Detector
FDR-D-EVO III
New
Pre-Op Planning Solution
Sectra 3D Trauma

Print article

Channels

Ultrasound

view channel
Image: The powerful machine learning algorithm can “interpret” echocardiogram images and assess key findings (Photo courtesy of 123RF)

Largest Model Trained On Echocardiography Images Assesses Heart Structure and Function

Foundation models represent an exciting frontier in generative artificial intelligence (AI), yet many lack the specialized medical data needed to make them applicable in healthcare settings.... Read more

Nuclear Medicine

view channel
Image: The multi-spectral optoacoustic tomography (MSOT) machine generates images of biological tissues (Photo courtesy of University of Missouri)

New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure

Imaging inflammation using traditional radiological techniques presents significant challenges, including radiation exposure, poor image quality, high costs, and invasive procedures. Now, new contrast... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.